Inoculating children and booster jabs will further fuel CDMO demand argues GlobalData’s Fiona Barry, who adds industry’s reliance on third-party manufacturers will not abate post-pandemic. Since the start of the pandemic, biopharma’s efforts and determination in developing and producing billions of vaccines and therapeutics have led to some companies and sectors benefitting from a COVID-19 windfall. The contract development and manufacturing organization (CDMO) sector is one such group, with both drug substance and drug product capacity proving crucial in the…

Details remain under wraps, but the $500 million investment will lead to Moderna’s first biomanufacturing facility outside of North America. Moderna, which sprang to the forefront of biopharma on the back of the success of its COVID-19 vaccine, announced yesterday it will invest up to $500 million into a facility on the African continent to support production of its messenger RNA portfolio. While the exact location (Africa is a big place!) has not yet been decided, a spokesperson for the…